Document:

EX-10.37

 Exhibit 10.37 

FEASIBILITY STUDY AND MATERIAL TRANSFER AGREEMENT 

This Feasibility Study and Material Transfer (the “Agreement”) is made as of the 6th of
January 2021 (the “Effective Date”) by and between TFF PHARMACEUTICALS, INC., a Delaware corporation, having an address at 2600 Via Fortuna, Suite 360, Austin, Texas 78746 (“TFF”), and NEURORX, INC., a
Delaware corporation having an address at 1201 North Market Street, Suite 111, Wilmington, Delaware 19801 (“NEURORX”). (TFF and NEURORX being separately, a “Party”, and together, the “Parties”).

 WHEREAS, NEURORX is a clinical stage, small molecule pharmaceutical company; 

WHEREAS, TFF is a licensee of certain intellectual property including certain know-how and trade secrets
relating to a process called “Thin Film Freezing” designed to improve solubility of poorly watersoluble drugs by generating dry powder particles with properties targeted for inhalation delivery (“TFF Technology”); 

WHEREAS, NEURORX desires that TFF conduct a feasibility study of the application of the TFF Technology to NEURORX’s proprietary RF-100 compound(s), and NEURORX will transfer such materials to TFF for such purpose; and 
 WHEREAS, TFF desires
to conduct the feasibility study for NEURORX using the NEURORX Materials. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises
set forth herein and with an intent to be legally bound, the parties hereto agree as follows: 
 1. Definitions Unless otherwise
specifically provided in this Agreement, the following terms shall have the following meanings: 
 1.1 “Affiliates” means, with respect to a
Person, any Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person. “Control” and, with correlative meanings, the terms “controlled
by” and “under common control with” means: (i) the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance,
resolution, regulation or otherwise, or (ii) to own fifty percent (50%) or more of the outstanding voting securities or other ownership interest of such Person. Notwithstanding the foregoing, the Parties agree that the University of Texas and
its researchers involved in the development of TFF’s TFF Technology shall be deemed to be Affiliates of TFF. 
 1.2 “NEURORX
Information” means any and all data and information provided by or on behalf of NEURORX to TFF in connection with the discussions and negotiations pertaining to, or in the course of performing, this Agreement, whether of a technical,
business or other nature, including information that relates to NEURORX’s or its Affiliates’ trade secrets, research and development activities, products, promotional material, and proprietary rights or business affairs, including the
NEURORX Materials, NEURORX’s Background IPR and those portions of the Results and the Feasibility Study Documentation that relate directly and exclusively to the NEURORX Materials or NEURORX’s Background IP. 

1.3 “NEURORX Materials” means NEURORX’s proprietary RF-100 compound(s), specifically relating to
the Feasibility Study which are provided by or on behalf of NEURORX that are proprietary to NEURORX and incorporate NEURORX Background IP. 

 Feasibility and MTA 

January 6 2021 
  

 1.4 “Background IPR” means any Intellectual Property Rights and know-how necessary in the performance of the Feasibility Study existing prior to entering into this Agreement or generated independently of the Feasibility Study under this Agreement, which are owned or controlled
by TFF or NEURORX (as the case may be) or to which TFF or NEURORX (as the case may be) has rights on the Effective Date or from time to time during the term of this Agreement. 

1.5 “Confidential Information” means all NEURORX Information and all TFF Information, respectively, disclosed to a Receiving Party by a
Disclosing Party pursuant to this Agreement in written, verbal or any other form. 
 1.6 “Disclosing Party” means the Party (or the
Affiliates of a Party) disclosing Confidential Information. 
 1.7 “Effective Date” means the date as set forth in the preamble to this
Agreement. 
 1.8 “Feasibility Study” means all those activities and services to be conducted by TFF as further set forth in the Statement
of Work. 
 1.9 “Feasibility Study Documentation” means any and all documents, records, notes, reports and other data relating to the
Feasibility Study, whether in written, electronic, video or other form. 
 1.10 “Intellectual Property Rights” or “IPR”
means confidential know-how, patent rights, 
 trademarks, service marks, trade names, design rights, copyright
(including rights in computer software) and any rights or property similar to any of the foregoing in any part of the world, whether registered or not, together with the right to apply for the registration of any such rights, and all rights or forms
of protection having equivalent or similar effect, in any part of the world. 
 1.11 “Loss” means any and all liabilities, claims, demands,
causes of action, damages, loss and expenses, including interest, penalties, and reasonable lawyers’ fees, court costs and expenses. 
 1.12
“Parties” has the meaning set forth in the preamble to this Agreement. 
 1.13 “Person” means an individual, sole
proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including
a government or political subdivision, department or agency of a government. 
 1.14 “Receiving Party” means the Party to whom Confidential
Information is disclosed. 
 1.15 “Results” means the data, information, documentation, reports, materials, samples, products, writings,
designs, computer software, processes, principles, methods and techniques, in any form, that are discovered, conceived, created, reduced to practice or otherwise generated as a result of or in connection the Feasibility Study by or on behalf of TFF
(whether solely or jointly with others), and any Intellectual Property Rights pertaining to any of the foregoing. 
 1.16 “Statement of
Work” means the document containing a description of the Feasibility Study and other terms and conditions pertaining thereto, attached hereto as Exhibit A - Statement of Work. 

1.17 “TFF Information” means any and all data and information provided by or on behalf of TFF in connection with the discussions and
negotiations pertaining to, or in the course of performing, this 

  
 2 

 Feasibility and MTA 

January 6 2021 
  

 Agreement, whether of a technical, business or other nature, including information that relates to TFF’s
or its Affiliates’ trade secrets, research and development activities, products, promotional material, and proprietary rights or business affairs, including the TFF Technology, TFF Materials, TFF’s Background IPR and the Results and the
Feasibility Study Documentation, except for those portions of the Results and the Feasibility Study Documentation that relate directly and exclusively to the NEURORX Materials or NEURORX’s Background IP. 

1.18 “TFF Materials” means the materials specifically relating to the Feasibility Study which are provided by or on behalf of TFF or its
Affiliates that are proprietary to TFF and its Affiliates and incorporate TFF Background IP, including TFF compounds, excipients and other raw materials, biological materials, processes, delivery devices and components thereof, packaging materials
and products and) any associated know-how and data. 
 1.19 “Third Party Claim” means any claim of a
third party for which indemnification is sought under Article 9 (Indemnification and Insurance). 
 2. Construction 

2.1 Except where the context requires otherwise, whenever used, the singular includes the plural, 

the plural includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the
phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience of reference only. The term “including” or
“includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties. 

2.2 If there is any inconsistency between the Statement of Work and the main body of this Agreement, the terms of the main body of this Agreement shall govern
unless the Statement of Work specifically references a Section of the main body of this Agreement and expressly states that such Section is intended to be changed or amended by the Statement of Work. 

2.3 The Statement of Work (as amended from time to time by agreement of the Parties in writing) 

forms part of this Agreement and has the same force and effect as if expressly set out in the body of the Agreement. Any reference to the Agreement includes
the Statement of Work. Any breach of the Statement of Work shall be deemed as a breach of this Agreement. 
 3. Feasibility Study 

3.1 Purpose; Conduct of the Feasibility Study. This Agreement provides the framework for a feasibility study of applicability of the TFF Technology to
the NEURORX Materials, to be provided by NEURORX to TFF. The Parties shall perform their respective obligations with respect to the Feasibility Study in accordance with this Agreement, in a good scientific manner and in compliance in all material
respects with all applicable laws and regulations. 
 3.2 Use of the NEURORX Materials 

(a) TFF acknowledges and agrees that all NEURORX Materials are and shall remain the exclusive property of NEURORX, and NEURORX acknowledges and
agrees that all TFF Materials are and shall remain the exclusive property of TFF. TFF shall not use NEURORX Materials, and NEURORX shall not use TFF Materials, for any purpose other than in connection with TFF’s performance of the Feasibility
Study pursuant to this Agreement and NEURORX’s evaluation of the Results. 

  
 3 

 Feasibility and MTA 

January 6 2021 
  

 (b) Each Party acknowledges that the NEURORX Materials and TFF Materials may be the subject
of issued patents and pending applications, and each Party agrees that nothing in this Agreement grants any rights to the TFF under the NEURORX Information or any rights to NEURORX under the TFF Information, except as may be necessary for conducting
the Feasibility Study and evaluating the Results as set forth herein. 
 (c) NEURORX hereby represents and warrants to TFF that: (i) no
NEURORX Materials delivered by or on behalf of NEURORX to TFF will be, at the time of shipment or delivery, adulterated, mislabeled or otherwise prohibited within the meaning of The Food, Drug and Cosmetic Act (“FD&C Act”) or similar
law of any other jurisdiction, nor an article which may not, under the provisions of Section 505 of the FD&C Act, be introduced into interstate commerce; (ii) to the best of NEURORX’s knowledge, no NEURORX Materials or the use
thereof infringe, or are alleged to infringe, the Intellectual Property Rights of any third party; (iii) all NEURORX Materials will be suitable for the purposes of the Feasibility Study and will have the same physical characteristics and
properties as set forth in the aforementioned product safety information; and (iv) prior to importation of NEURORX Materials by or on behalf of NEURORX to a TFF facility from another country, if applicable, NEURORX shall have obtained all
required foreign approvals required for handling, storing or using the NEURORX Materials. 
 3.3 Licenses. NEURORX grants TFF a free non-exclusive license, with a right to sublicense to third parties (including the University of Texas) to use the NEURORX Materials solely for the purpose of performing the Feasibility Study. The licenses granted in
this Section 3.3 shall expire upon the expiration or termination of this Agreement. 
 3.4 Subcontracting. TFF may engage or
make use of sub-contractors in the performance of the Feasibility Study, including The University of Texas at Austin. Any such permitted subcontract shall be subject to the applicable terms and conditions of
this Agreement, provided, however, that no such subcontract shall release TFF from any of its obligations under this Agreement except to the extent such obligations are satisfactorily performed by such subcontractor in accordance with this
Agreement. 
 3.5 Tools and Equipment. Unless otherwise set forth in the Statement of Work, TFF shall furnish, at its own expense, all tools,
equipment, facilities, materials (other than NEURORX Materials) and other resources necessary or useful to conduct and complete the Feasibility Study. 
 3.6
Health, Safety, Environmental. NEURORX shall provide all necessary information it has in its possession relating to the health, safety and environment aspects of the NEURORX Materials. In addition, NEURORX shall inform TFF of any potential
process hazards which it has knowledge of and which relate to the Feasibility Study. 
 3.7 Updates and Reports. If requested by NEURORX the Parties
shall meet (either in person or by teleconference or video-conference) at regular intervals during the term of this Agreement to discuss the progress of the Feasibility Study. Any interim or final reports to be provided by TFF to NEURORX shall
include a detailed summary of all work done and Results generated. 

  
 4 

 Feasibility and MTA 

January 6 2021 
  

 4. Ownership of Results; New IPR and Background IPR. 

4.1 Results. TFF shall disclose to NEURORX the Results and shall deliver to NEURORX, and NEURORX shall be entitled to use, for the sole purpose of
evaluating the Results, a copy of the Results and all Feasibility Study Documentation. 
 4.2 Ownership of Results and New IPR. TFF shall own all
right, title and interest in and to all Results, the Feasibility Study Documentation and all inventions, discoveries, innovations and know-how and including all rights to patent any of the foregoing that is an extension of or improvement to
TFF’s Background IPR or that otherwise relates to the process of conducting dry powder formulations. (collectively “New TFF IPR”). NEURORX shall own all right, title and interest in and to all Results, the Feasibility Study
Documentation and all inventions, discoveries, innovations and know-how and including all rights to patent any of the foregoing that is an extension of or improvement to NEURORX’s Background IPR or that
otherwise relates to the NEURORX Materials (“New NEURORX IPR”). Notwithstanding the foregoing, TFF and The University of Texas at Austin shall be allowed to use and disclose the Results and the Feasibility Study Documentation that
relate directly and exclusively to the NEURORX Materials in the course of their internal research and educational activities. The University of Texas at Austin shall also be allowed to refer to the Results and the Feasibility Study Documentation
that relate directly and exclusively to the NEURORX Materials in future academic or scientific publications. 
 4.3 Patent Rights. 

(a) NEURORX shall have no right to patent the New TFF IPR. NEURORX hereby assigns and transfers and shall cause all NEURORX individuals
involved in the Feasibility Study to assign and transfer, without additional consideration, to TFF (or such designee) all right, title and interest in and to any and all New TFF IPR throughout the world. NEURORX shall, and shall cause all NEURORX
individuals involved in the Feasibility Study to execute, or cause to be executed, all papers necessary for TFF to apply for, prosecute and defend patents covering the New TFF IPR, including assignments to TFF (or such designee) as necessary or
useful to vest all right, title and interest in and to the New TFF IPR in TFF (or such designee), without additional consideration. 
 (b)
TFF shall have no right to patent the New NEURORX IPR. TFF hereby assigns and transfers and shall cause all TFF individuals involved in the Feasibility Study to assign and transfer, without additional consideration, to NEURORX (or such designee) all
right, title and interest in and to any and all New NEURORX IPR throughout the world. TFF shall, and shall cause all TFF individuals involved in the Feasibility Study to execute, or cause to be executed, all papers necessary for NEURORX to apply
for, prosecute and defend patents covering the New NEURORX IPR, including assignments to NEURORX (or such designee) as necessary or useful to vest all right, title and interest in and to the New NEURORX IPR in NEURORX (or such designee), without
additional consideration. 
 (c) NEURORX and TFF shall work cooperatively and in good faith to patent and secure other rights in and to any
IPR, other than the New TFF IPR or New NEURORX IPR, generated by way of the Feasibility Study under this Agreement throughout the world (“Joint IPR”). Each Party shall, and shall cause all individuals from that respective Party
involved in the Feasibility Study, to execute or cause to be executed all papers necessary for the Parties to apply for, prosecute and defend patents and other intellectual property covering the Joint IPR, including securing the necessary
assignments to each respective Party from such individuals as necessary or useful to vest all right, title and interest in and to the Joint IPR in the respective Party, without additional consideration. As between the Parties, NEURORX shall be
responsible for filing, prosecution maintenance and defending Joint IPR in each jurisdiction in which patent applications and patents protecting such Joint IPR are filed, granted and maintained. Should either Party decline to participate in or
continue to support the filing, prosecution, maintenance and/or defense of any Joint IPR, that Party shall promptly execute or cause to be executed all papers necessary to assign the rights to such Joint IPR to the other Party. 

  
 5 

 Feasibility and MTA 

January 6 2021 
  

 4.4 Background IPR Each Party owns and shall continue to own its own Background IPR. Neither Party
shall be entitled to any right, title or interest in or to the Background IPR of the Party except as expressly provided for in this Agreement for the limited purpose of conducting the Feasibility Study and evaluating the Results. 

5. Confidentiality 
 5.1 Ownership of
Confidential Information. Except as otherwise provided in this Agreement, any Confidential Information which is disclosed by or on behalf of one Party to the other in connection with this Agreement, including copies and reproductions thereof,
shall remain the property of the Disclosing Party. 
 5.2 Confidentiality Undertaking. The Receiving Party undertakes: (a) to use the
Confidential Information solely and exclusively for the purposes of or as agreed in this Agreement and not to use the Confidential Information for any other purpose whatsoever, (b) to maintain the confidentiality of the Confidential Information
and not to disclose it directly or indirectly to any other Person, except as permitted in this Agreement, and (c) at the request of the Disclosing Party, to return, delete or destroy all copies of the Confidential Information, in whatever form
it is held. 
 5.3 Permitted Disclosures and Use 

(a) Notwithstanding Section 5.2, the Receiving Party may disclose the Disclosing Party’s Confidential
Information to any of its Affiliates and to officers, directors and other employees, consultants and agents of the Receiving Party or of its Affiliates on a purely need to know basis in so far and to the extent absolutely necessary or required for
the purposes of carrying out their respective obligations under the Agreement and in order to fulfil the purpose of this Agreement, provided that the Receiving Party shall ensure that: (i) each such Person to whom Confidential Information is to
be disclosed is made aware of the obligations contained in this Agreement prior to such disclosure and undertakes to adhere to the terms of this Agreement as if it were a party to it, (ii) each such Person to whom Confidential Information is
disclosed pursuant to this Section 5.3(a), complies with the terms of this Agreement and adopts the same level of security and degree of care as set out in this Agreement, and (iii) it shall be liable for, and shall
indemnify the Disclosing Party against, any breach, default or non-compliance of the provisions of this Agreement by each such Person. 

(b) Nothing in Section 5.2 shall preclude disclosure of any Confidential Information required by any governmental,
quasi-governmental or regulatory agency or authority or court entitled by law or regulation to disclosure of the same, or which is required by law or regulation to be disclosed, provided that the Receiving Party promptly notifies the Disclosing
Party when such requirement to disclose has arisen, to enable the Disclosing Party to seek an appropriate protective order, to make known to the relevant agency, authority or court the proprietary nature of the Confidential Information, and to make
any applicable claim of confidentiality. The Receiving Party agrees to cooperate in any appropriate action which the Disclosing Party may decide to take. If the Receiving Party is advised to make a disclosure in accordance with this section, it
shall only make a disclosure to the extent to which it is obliged. 

  
 6 

 Feasibility and MTA 

January 6 2021 
  

 (c) Exceptions. The provisions of Section 5.2 shall not
apply to any Confidential Information which the Receiving Party can demonstrate to the reasonable satisfaction of the Disclosing Party: (i) is or becomes known publicly through no fault of the Receiving Party, or (ii) was, prior to
disclosure to it pursuant to this Agreement, purchased or otherwise legally acquired by the Receiving Party at any time from a third party having good title thereto and the right to disclose the same, or (iii) is already known to the Receiving
Party and such Receiving Party can show such information as being known by written records, or (iv) is independently generated by the Receiving Party or any of its Affiliates without any recourse or reference to the Confidential Information
disclosed by the Disclosing Party. 
 (d) Duration. The obligations of each Party in this Section 5 shall
survive for a period of five (5) years from the date upon which disclosure of such Confidential Information was made. 
 (e) Press
Releases and Use of Name. Neither Party shall make any public announcement relating to this Agreement or the transactions covered by it without the prior written approval of the other Party. 

6. Compliance with Laws. Each Party represents that it will perform its obligations under this Agreement in compliance with all applicable
Federal, State, local and foreign laws and regulations (“Laws”), including, without limitation, the Export Administration Act and the regulations thereunder, and will use reasonable efforts to cause its Affiliates and subcontractors
performing in connection with this Agreement to operate their business in compliance with all applicable Laws. 
 7. Term and Termination 

7.1 Term. This Agreement shall commence upon the Effective Date and shall continue until the first to occur of either the completion of the Feasibility
Study or one year from the Effective Date, unless this Agreement is earlier terminated in accordance with this Article 7. 
 7.2 Termination for
Breach. Without prejudice to any other rights or remedies which may be available to them, either Party may terminate this Agreement with immediate effect by giving written notice of termination to the other Party in any of the following
circumstances: 
 (a) if the other Party commits a material breach or a series of minor breaches of a recurring nature of any of the
provisions of this Agreement and, in the case of a breach capable of being remedied, fails to remedy that breach within thirty (30) days of receiving written notice specifying that breach and requiring the same to be remedied; or 

(b) this Agreement may be terminated by either party without cause at any time by the provision of thirty (30) days’ written notice.

 7.3 Consequences of Termination. Upon expiration or earlier termination of this Agreement: (a) TFF shall promptly cease performance of the
Feasibility Study, (b) each Party return to the other Party all NEURORX Information or TFF Information in such Party’s possession (except one copy of such NEURORX Information may be retained by TFF for archival purposes), (c) TFF shall as
promptly as practicable deliver to NEURORX copies of solely those Results and Feasibility Study Documentation directly relating to any New NEURORX IPR, (d) TFF shall at NEURORX’s option, either destroy or return (at NEURORX’s expense)
to NEURORX all NEURORX Materials, provided that in the case of destruction TFF shall certify in writing to NEURORX that such NEURORX Materials have been destroyed. For the avoidance of doubt, termination of this Agreement shall not affect any rights
and obligations of the Parties that accrued prior to termination. 

  
 7 

 Feasibility and MTA 

January 6 2021 
  

 7.4 Survival. The respective rights and obligations of the Parties under Article 1, Sections 3.2, 3.3,
3.4, 3.5, Articles 5, 6, 7, 8, Sections 10.4, and this Section 7.4 shall survive indefinitely the termination or expiration of this Agreement. [to be finalized upon finalization of the Agreement] 

8. Representations and Warranties. 
 8.1 Mutual
Representations. Each Party represents, warrants and covenants to the other Party that: (a) it has full power and authority, and has taken all necessary actions and has obtained all necessary authorizations, licenses, consents and approvals
required, to execute and perform this Agreement, (b) its performance of the Feasibility Study does not, and shall not, breach any agreement that obligates such Party to keep in confidence any trade secrets or confidential information of any
other third party or to refrain from competing, directly or indirectly, with the business of any other party, (c) as far as it is aware the performance of the Feasibility Study does not infringe any IPR of any third party, and (d) neither
Party nor any individual involved in the performance of the Feasibility Study has been debarred or is subject to debarment or has otherwise been disqualified or suspended from performing scientific or clinical investigations or otherwise subjected
to any restrictions or sanctions by the FDA or any other governmental or regulatory authority or professional body with respect to the performance of scientific or clinical investigations. 

8.2 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN SECTION 8.1 OF THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,
MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

9. Indemnification; Limitation on Damages. 
 9.1
Indemnification. Each Party shall defend, indemnify and hold harmless the other Party, its Affiliates and its and their respective officers, directors, partners, shareholders, employees and agents from and against any and all Losses incurred
by them to the extent resulting from or arising out of or in connection with any Third Party Claim against them to the extent resulting from or arising out of or in connection with: (a) any breach of any obligation in this Agreement by the
other Party or (b) the inaccuracy or breach of any representation or warranty made by the other Party in this Agreement, except to the extent such Losses arise as a result of the negligence, fraud, willful misconduct or wrongful act of the
indemnified Party, its Affiliates or its or their respective officers, directors, partners, shareholders, employees or agents. 

  
 8 

 Feasibility and MTA 

January 6 2021 
  

 9.2 Limitations. 

(a) EXCEPT WITH RESPECT TO (I) BREACH OF THE CONFIDENTIALITY OBLIGATIONS SET FORTH IN ARTICLE 5 OR (II) OR FOR AMOUNTS SOUGHT
BY THIRD PARTIES IN CLAIMS THAT ARE SUBJECT TO THE PARTIES’ RESPECTIVE INDEMNITY OBLIGATIONS UNDER SECTION 9.1, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR ANY CONSEQUENTIAL, SPECIAL, INDIRECT, INCIDENTAL EXEMPLARY OR
PUNITIVE DAMAGES OR FOR LOSS OF PROFITS, LOSS OF BUSINESS OR LOSS OF REVENUE, SUFFERED BY THE OTHER PARTY HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, AND WHETHER OR NOT SUCH PARTY WAS OR SHOULD HAVE BEEN AWARE OR ADVISED OF THE POSSIBILITY OF
SUCH DAMAGE. 
 (b) Maximum Liability. EXCEPT WITH RESPECT TO (I) BREACH OF THE CONFIDENTIALITY OBLIGATIONS SET FORTH IN
ARTICLE 5 OR (II) OR FOR AMOUNTS SOUGHT BY THIRD PARTIES IN CLAIMS THAT ARE SUBJECT TO THE PARTIES’ RESPECTIVE INDEMNITY OBLIGATIONS UNDER SECTION 9.1, IN NO EVENT SHALL TFF’S AND ITS AFFILIATES’ TOTAL CUMULATIVE
LIABILITY FOR ALL CLAIMS HEREUNDER EXCEED THE CUMULATIVE SUM OF ALL AMOUNTS PAID BY NEURORX TO TFF UNDER THIS AGREEMENT. 
 10. Miscellaneous

 10.1 Assignment. Neither Party may assign its rights or its obligations under this Agreement, whether by operation of law or otherwise, in whole or
in part, without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be
enforceable by, the Parties and their respective successors and permitted assigns. Any attempted assignment, delegation or subcontracting in violation of this Section 10.1 shall be void and of no effect. 

10.2 Governing Law. The interpretation and construction of this Agreement shall be governed by the laws of the State of Texas, excluding any conflicts
or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

10.3 Jurisdiction. The Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the federal and state courts located in
Travis County in the State of Texas or any action, suit or proceeding arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding related thereto except in such courts. 

10.4 Notice Requirements Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall
be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their
respective addresses specified in this Section 10.4 below or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this
Section 10.4. Such notice shall be deemed to have been given as of the date delivered by hand or on the second business day (at the place of delivery) after deposit with an internationally recognized overnight delivery
service. This Section 10.4 is not intended to govern the day-to-day business communications necessary between the Parties in performing their
obligations under the terms of this Agreement. 

  
 9 

 Feasibility and MTA 

January 6 2021 
  

 Address for Notice: 

To TFF: 
 TFF PHARMACEUTICALS, INC. 

2600 Via Fortuna, Suite 360 

Austin, Texas 78746 
 Attn: Glenn
Mattes 
 To NEURORX: 
 NEURORX, INC. 

1201 North Market Street, Suite 111 

Wilmington, Delaware 19801 
 Attn:
Jonathan Javitt, with email to jjavitt@neurorxpharma.com 
 10.5 Relationship of the Parties. The status of a Party under this Agreement shall be that
of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency relationship between the Parties or, except as otherwise expressly provided in this Agreement, as granting either
Party the authority to bind or contract any obligation in the name of or on the account of the other Party, or to make any statements, representations, warranties or commitments on behalf of the other Party. All persons employed or engaged by a
Party shall be employees or self-employed contractors of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment or engagement shall be for the account and expense of such Party. 

10.6 Further Assurances. Each Party agrees to cooperate fully with the other party and to execute such further instruments, documents and agreements and
to give such further written assurances as may be reasonably requested by the other Party to evidence and reflect the transactions described herein and contemplated hereby and to carry into effect the intents and purposes of this Agreement. 

10.7 Force Majeure. Each Party shall be relieved of its obligations to the extent and for the duration that fulfillment of its obligations shall be
prevented by acts beyond the reasonable control of the Party affected. 
 10.8 Entire Agreement; Amendments. This Agreement constitutes the entire
agreement between the Parties with respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. All Exhibits referred to in this
Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. Any amendment or modification of this Agreement must be in writing and be signed by authorized representatives of both Parties. 

10.9 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together
be deemed to constitute one agreement. The Parties agree that execution of this Agreement by industry standard electronic signature software and /or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original
signatures, and that in any proceeding arising under or relating to this Agreement, each Party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the
executed agreement electronically. 

  
 10 

 Feasibility and MTA 

January 6 2021 
  

 [Signatures appear on following page] 

THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above. 

 

									
	SIGNED for and on behalf of	 	    	  	SIGNED for and on behalf of
			
	NEURORX, INC.	 		  	TFF PHARMACEUTICALS, INC.
			
	 /s/ Jonathan C. Javitt MD, MPH
	 		  	 /s/ Glenn Mattes

	Signature	 		  	Signature
					
	Name:	 	Jonathan C. Javitt, MD, MPH	 		  	Name:	  	Glenn Mattes
	Title:	 	CEO and Chairman	 		  	Title:	  	CEO
	Date:	 	1/28/2021	 		  	Date:	  	01/27/2021

  
 11 

 Feasibility and MTA 

January 6 2021 
  

 Exhibit A – Statement of Work 

This Statement of Work is incorporated into and forms part of the Agreement. Terms defined in the main body of the Agreement have the same meaning when
used in this Statement of Work. 
 [To be completed and mutually agreed upon] 

Principal Investigators: 
 All laboratory work performed
under this Statement of Work will be at the direction of Bill Williams and Rong Cui (the “Principal Investigators”) at the Principal Investigators’ laboratories at the University of Texas at Austin, pursuant to that certain Amended
and Restated Technology Validation Agreement entered into by and between TFF Pharma and the University of Texas at Austin dated as of April 13, 2020, as may be amended from time to time. 

  
 12EX-10.38

 Exhibit 10.38 

[Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with
asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.] 

MANUFACTURING SUPPLY AGREEMENT 
  

					
	Between:	  	 NeuroRx, Inc.
 a Delaware corporation
	  	(“BUYER”)
		
	And:	  	Nephron SC, Inc., and Nephron Pharmaceuticals Corporation, subsidiaries of Nephron, Inc. d/b/a NEPHRON PHARMACEUTICALS CORPORATION
		  	a Delaware corporation	  	(“SUPPLIER”)
			
	Effective Date:	  	August 25th, 2020	  	

 RECITALS 

A. BUYER is engaged in the business of development and distribution of pharmaceutical products. 

B. SUPPLIER is engaged in the business of developing, manufacturing, and supplying pharmaceutical products. 

C. BUYER desires to have SUPPLIER manufacture and supply certain pharmaceutical products as provided in this Agreement and SUPPLIER desires to provide BUYER
with such services. 
 NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
Definitions. In addition to other terms that may be defined elsewhere in this Agreement, 
 the following capitalized terms shall have the
following meanings: 
 1.1 “Cancellation” shall mean the cancellation of all or any part of a Purchase Order by BUYER. 

1.2 “Carrier” shall mean any person or entity engaged in the transportation of goods as shall be designated to by BUYER. 

1.3 Intentionally left blank. 

1.4 “Delivery Date” shall mean the date upon which SUPPLIER is to deliver the Product to a Carrier pursuant to a Purchase Order. 

1.5 “Delivery and Shipping Instructions” shall mean the delivery and shipping instructions that BUYER provides to SUPPLIER pursuant
to a Purchase Order. 

 1.6 “Facilities” shall mean SUPPLIER’s manufacturing facilities located at
4500 12th Street Extension, West Columbia, SC 29172. 
 1.7 “FDA” shall mean
the United States Food and Drug Administration or any successor agency. 
 1.8 “cGMP” shall mean applicable current Good
Manufacturing Practices as defined by 21 Code of Federal Regulations Section 210, 211 et. seq. or as required by the FDA and any other Regulatory Authority whose approval of the Product is necessary or who otherwise regulates the Product. 

1.9 “Non-Conforming Product” means any Product that is 

(i) defective in materials (if SUPPLIER is responsible for producing materials from its own sources) or workmanship, 

(ii) does not conform to the Product Specifications or USP, 

(iii) does not comply with the Quality Agreement or was not manufactured in full compliance with cGMPs, or 

(iv) is encumbered by any lien or defect in title. 

1.10 “Product Performance Characteristics” shall mean performance characteristics of a Product including, but not limited to, safety,
efficacy, potency, shelf life, and application. 
 1.11 ”Product Price” shall mean the price(s) of the Product(s) as set forth in
Exhibit C. 
 1.12 “Product” means the product(s) listed on Exhibit A manufactured by SUPPLIER for BUYER pursuant to this
Agreement. Non-Conforming Product is not deemed Product under this Agreement. 
 1.13 “Purchase
Orders” means the orders for Product placed by BUYER pursuant to and in accordance with Section 4. 
 1.14 “Purchase
Price” shall mean the product of multiplying the Product Price by the quantity of Product delivered. 
 1.15 “Quantity
Ordered” shall mean the quantity of Product ordered by BUYER pursuant to a Purchase Order. 

 1.16 “Regulatory Authority” means the FDA and the regulatory authority of any
governmental unit that regulates the import, distribution, manufacturing, marketing, labeling, or sale of pharmaceutical products. 
 1.17
“Specifications” means the ingredient list, formulation, manufacturing instructions, testing and handling requirements, quality criteria, labeling and packaging requirements and other directions for the manufacture and supply of the
Product as provided by BUYER and specifically set forth in Exhibit B, as the same may be amended from time to time by written agreement of the parties. However, regardless of whether set forth in Exhibit B, Specifications do not include BUYER’s
claims regarding Product Performance Characteristics. 
 1.18 “Term” means the period that this Agreement is effective as set forth
in Section 12. 
 1.19 “Territory” means the United States and its territories and commonwealths, including but not limited to
the Commonwealth of Puerto Rico. 
 1.20 “USP” means United States Pharmacopoeia. 

2. Agreement to Manufacture and Purchase. 

2.1 Exclusive Manufacture. Pursuant to and in accordance with the terms and conditions of this Agreement, and in response to Purchase
Orders received from time to time, SUPPLIER shall exclusively manufacture and supply the Product to BUYER, and BUYER shall purchase and accept delivery of the Product from SUPPLIER in accordance with Section 2.2. During the Term of this
Agreement and for one (1) year thereafter, SUPPLIER shall not develop, manufacture, supply, distribute or market any Product or its bioequivalent in any packaging or presentation for or on behalf of itself or any third party worldwide outside
of this Agreement, unless (a) SUPPLIER purchases an approved NDA or ANDA for the Product from BUYER or a third party, and such purchased NDA or ANDA is in no way derived from Product information provided by BUYER or (b) BUYER terminates
this Agreement pursuant to section 12.8 or section 12.10. SUPPLIER shall manufacture and supply the Product in accordance with the Specifications, cGMP, and the provisions of this Agreement. 

2.2 Purchase Requirements. SUPPLIER shall serve as BUYER’s primary supplier of the Product, supplying 100% of BUYER’s annual
requirements for containers of the Product each year. 
 2.3 Delay. Notwithstanding anything to the contrary in this Agreement, in the
event that SUPPLIER is unable to deliver Product on or before the Delivery Date, BUYER shall have the right to cancel all or any portion of Purchase Orders for Product not delivered under the terms of section 4.3 and 4.4 of this Agreement. 

 2.4 Alternate Site. BUYER shall have the right to qualify
an alternate site for manufacturing of Products under the respective Product registrations. The alternate manufacturing site qualified pursuant to this section may only be used to satisfy 100% of BUYER’s purchase requirements in the event
SUPPLIER is unable to meet BUYER’s Purchase Orders for a specific Product more than three (3) times in a quarter or for more than ninety (90) consecutive days for any individual Purchase Order. 

2.5 Quality Agreement. The parties shall enter into a quality agreement for each Product covered by the terms of this Agreement on terms
mutually agreeable to the parties as soon as practicable. Each quality agreement shall contain provisions consistent with cGMP and all other applicable laws and regulations. Prior to SUPPLIER’s production and supply of the first batch or lot of
any Product, BUYER’s program manager and quality assurance managers shall conduct a quality inspection of SUPPLIER’s facility. To the extent BUYER’s program manager and/or quality assurance managers are not satisfied with the
facility, they shall provide SUPPLIER with a written notice setting forth BUYER’s objections. SUPPLIER shall, at its sole expense, correct or modify all items objected to by BUYER and demonstrate compliance with BUYER’s requirements as
soon as practicable following receipt of BUYER’s written notice. In the event SUPPLIER does not do so within a reasonable time, BUYER shall have the right to suspend orders under this Agreement with respect to any affected Product, until
corrected. Notwithstanding Company’s quality inspection and other activities pursuant to this section, nothing in this section shall alter SUPPLIER’s sole responsibility for its compliance with cGMP and applicable laws and regulations, and
all other applicable requirements under this Agreement, or to release Supplier from its obligations with respect to such compliance. 
 2.6
Technical Transfer. BUYER and SUPPLIER shall work together to (i) effectively transfer the manufacture and testing of the Product to SUPPLIER’s facilities, and (ii) add a second packaging configuration for Products. 

The Parties shall be responsible for performing the activities set forth in Exhibit F at each Party’s sole cost and expense. BUYER
shall be responsible for registration and payment of all fees associated with the file. SUPPLIER shall provide technical information necessary to support registration process. SUPPLIER shall be responsible for US FDA establishment fees. 

3. Price and Payment. 
 3.1
Prices. BUYER shall pay to SUPPLIER, in United States Dollars, the Product Price as set forth in Exhibit C. 
 3.2 Customs and
Other Duties. All duties and charges, including state government levy and customs duties, in the country in which SUPPLIER’s manufacturing facility is located, including any duties, taxes, VATs or similar charges arising with respect to the
manufacture, sale, exportation and shipment of the Product by SUPPLIER to BUYER, shall be borne and paid by BUYER. 

 3.3 Price Adjustments. Commencing on the first day that is six (6) months after
the date hereof, and continuing on each January 1st thereafter during the Term, and with BUYER’s prior approval, SUPPLIER shall be able to adjust the Product Price. SUPPLIER shall use
commercially reasonable efforts to prevent increases in the Product Price. In the event the Product Price increases, SUPPLIER shall provide sufficient documentary evidence of any such increases in the Product Price. For clarity, entire amounts of
decreases will be passed on to BUYER through reductions to Product Price. 
 3.4 Product Payment. SUPPLIER shall invoice BUYER upon
delivery of the Product to the Carrier. Payment of the Purchase Price shall be due to SUPPLIER thirty days (30) days after the date of SUPPLIER’s invoice. In the event of a delay in shipment of Product caused by BUYER, the invoice shall be
dated as of the QA release date by SUPPLIER. In the event of production delays in excess of thirty (30) days caused by BUYER’s failure to supply BUYER Supplies (as defined below) to SUPPLIER, then SUPPLIER has the right to invoice BUYER
for the in-process materials. 
 3.5 Failure to Pay. In the event BUYER fails to make any
payment more than ninety (90) days after it is due: (i) BUYER shall pay a monthly late payment penalty equal to 1.0% of the amount due but unpaid sixty (60) days from the due date and as of each thirty (30) day period thereafter,
and (ii) SUPPLIER may, at its sole discretion, discontinue or withhold manufacturing, supplying, or delivery of additional Product until such payment of all overdue and outstanding amounts are made. 

3.6 Financial Audit. Each Party shall maintain its books and records related to manufacture, sourcing and sale of Product in accordance
with its usual business practices. Either Party may conduct a financial audit of the other Party to confirm such Party’s compliance with financial terms of this Agreement upon thirty (30) days written notice and not more often than once a
year. The audit will be conducted by the party and/or an independent public accounting firm and shall be conducted at expense of the Party initiating the audit. 

4. Orders. 
 4.1 Forecasts.
BUYER shall provide to SUPPLIER on a quarterly basis a twelve-month, non-binding, rolling forecast. All orders require a formal Purchase Order in accordance with Section 4.2. 

4.2 Terms. Purchase Orders shall be in writing on BUYER’s standard purchase order form. Each Purchase Order shall specify the
Quantity Ordered, Delivery Date, and Delivery and Shipping Instructions, and shall be delivered to SUPPLIER not less than 30 days prior to the Delivery Date. Unless otherwise expressly agreed in writing by SUPPLIER, terms contained in a Purchase
Order, including, but not limited to, preprinted terms and conditions, that are inconsistent with the terms of this Agreement, shall not apply or be enforceable by BUYER. The volume of a minimum Purchase Order of Product shall be at least one
commercial batch of Product unless an alternate configuration or quantity is mutually agreed upon by the parties. 

 4.3 Receipt of Purchase Order. Upon SUPPLIER’s confirmation of receipt of a
Purchase Order which otherwise complies with the terms of this Agreement, SUPPLIER shall use all commercially reasonable efforts to manufacture and supply the Product in accordance with the Specifications in the quantity and on the dates set forth
in such Purchase Orders, and except as otherwise provided in this agreement, BUYER shall be obligated to purchase and take delivery of the Product in such quantities and on such dates. Purchase Orders shall be deemed accepted by SUPPLIER unless
SUPPLIER rejects such Purchase Order in writing within five (5) days of receipt. 
 4.4 Rescheduling. BUYER may reschedule
delivery under a Purchase Order from its originally scheduled ship date provided that it so informs SUPPLIER on or before five (5) calendar days prior to the scheduled shipment date stated in the applicable Purchase Order without any
rescheduling or any other charges. SUPPLIER may reschedule delivery under a Purchase Order from its originally scheduled ship date provide that it so informs BUYER on or before fifteen (15) calendar days prior to the scheduled shipment date
stated in the applicable Purchase Order without any rescheduling or any other charges. 
 4.5 Cancellation of Purchase Orders. In the
event of the cancellation of a Purchase Order that will not be filled at a later date, BUYER will be responsible for the cost to SUPPLIER of any materials received by SUPPLIER whose use is exclusively for manufacturing of the Product, but only to
the extent that the materials were to be used in fulfilling the cancelled Purchase Order. Upon payment by BUYER for such materials, they shall become the property of the BUYER and SUPPLIER shall disposition such materials as BUYER directs and at
BUYER’s expense. 
 5. Raw Materials and Other Supplies. 

5.1 BUYER Supplies. Until SUPPLIER is able to procure some or all BUYER Supplies, BUYER shall be responsible for providing and supplying
SUPPLIER with the Active Pharmaceutical Ingredient (“API”) for the Product, other raw materials, and labeling necessary for SUPPLIER to manufacture and supply the Product to BUYER in accordance with the terms of this Agreement and any
Purchase Order (“BUYER Supplies”). See Section 5.5. BUYER Supplies shall include, but are not limited to, those supplies set forth on Exhibit D. Title to BUYER Supplies, provided by BUYER, shall at all times remain with BUYER. In
addition, title to any BUYER equipment (whether a fixture at any of the Facilities or not) shall remain with BUYER and SUPPLIER shall not obtain any ownership interests in such equipment without BUYER’s written consent. SUPPLIER may return, at
BUYER’s expense, all unused BUYER Supplies to BUYER at the end of the Term, provided that BUYER shall not be responsible for purchasing more than a six (6) month supply of Raw Materials pursuant to the submitted forecast. 

 5.2 Delivery. Until SUPPLIER is able to procure some or all BUYER Supplies (not to
include API), BUYER shall deliver or procure delivery of BUYER Supplies to SUPPLIER in sufficient quantities, quality, and condition, and at least 60 days in advance of a required Delivery Date, to enable SUPPLIER to meet its obligations under this
Agreement and the relevant Purchase Order. Where applicable, BUYER Supplies shall be provided with appropriate release documentation. BUYER’s failure to timely satisfy the requirements of this section shall excuse SUPPLIER’s failure to
meet a required Delivery Date to the extent that such BUYER’s failure caused or materially contributed to SUPPLIER’s failure. 

5.3 Supply Failure. For each binding Purchase Order on which SUPPLIER fails to deliver at least 90% of the binding, ordered quantity of
the Product within fifteen (15) days after the scheduled delivery date, SUPPLIER shall be liable to BUYER for (i) any cost difference for acquiring the shorted amount from an alternate site, and (ii) the greater of (a) 10% of the Product
Price for the units not timely delivered, or (b) any amounts paid by BUYER to any customer as penalties due to SUPPLIER’s failure to supply any Product on a timely basis (collectively the “Supply Failure Penalty”). BUYER shall
have the right to offset the Supply Failure Penalty against any Profit Split owed to SUPPLIER. 
 5.4 SUPPLIER Supplies. SUPPLIER
shall be responsible to provide and supply, at no additional cost to BUYER, the supplies listed in Exhibit E (the “SUPPLIER Supplies”). 

5.5 Raw Material Testing. SUPPLIER may, with BUYER’s prior approval, order the API directly from BUYER’s vendor. The API may
be delivered directly from BUYER’s vendor to SUPPLIER at BUYER’s expense. With each shipment of API, BUYER shall provide, or require the vendor to supply, SUPPLIER with a completed copy of the vendor’s certificate of analysis for the
API containing test results. BUYER may elect to have SUPPLIER undertake identification testing of each shipment and/or testing for compliance with the Specifications. If the API fails any testing by SUPPLIER, SUPPLIER will immediately provide BUYER
notice of such failure along with details of the testing and reason(s) for failure, and SUPPLIER shall be excused from its obligation to manufacture or supply Product to BUYER until API meeting approved Specifications is delivered to SUPPLIER. Upon
such delivery, SUPPLIER shall have a reasonable time in which to supply Product to BUYER that satisfies and complies with the Specifications. 

5.6 Active Pharmaceutical Ingredient and Product Handling. SUPPLIER shall store the Active Pharmaceutical Ingredient and the Product at
a temperature and in accordance with other special handling requirements set forth in the Specifications, DEA (if applicable) and FDA cGMP. 

5.7 Labeling. Regardless of whether BUYER or SUPPLIER provides the labeling for the Product under this section, BUYER shall provide the
wording for all labeling and shall be solely responsible for compliance with all laws and regulations regarding the content of labeling. SUPPLIER shall label the Product as set forth in the Specifications. 

 5.8 Packaging. SUPPLIER shall package the Product for shipment in accordance with the
Specifications, as approved by FDA. 
 5.9 Shipping. Product shall be delivered to BUYER at SUPPLIER’s shipping dock. SUPPLIER
shall indicate the Purchase Order number or other identifying number on all packing slips, as reasonably directed by BUYER. 
 5.10 Risk
of Loss. BUYER shall bear the risk of loss of BUYER Supplies by reason of theft, casualty, or other cause beyond SUPPLIER’s reasonable control prior to delivery of BUYER Supplies to SUPPLIER. SUPPLIER shall bear the risk of loss of
(i) SUPPLIER Supplies and (ii) the Product (to the extent of value added by SUPPLIER over the value of BUYER Supplies, which become a part of such Product) until delivery of the Product to the Carrier, at which time risk of loss shall pass
to BUYER. Notwithstanding anything to the contrary contained herein, in no event shall SUPPLIER’s liability exceed the cost of BUYER Supplies lost, damaged, destroyed, or otherwise unusable. Notwithstanding the foregoing, any loss or damage to
BUYER Supplies, SUPPLIER Supplies, or the Product resulting from acts by SUPPLIER taken in accordance with the Specifications, cGMP, or BUYER instructions shall be borne by BUYER. SUPPLIER shall bear the risk of loss of BUYER Supplies due to
SUPPLIER’s willful misconduct or negligence, including but not limited to SUPPLIER’s failure to comply with the Specifications, cGMPs, or BUYER instructions. 

5.11 BUYER Supplies Interruption. If BUYER reasonably foresees at any time that it is likely to become unable to supply or procure
supply of BUYER Supplies to SUPPLIER in the next six (6) months from that time, BUYER shall provide prompt notice to SUPPLIER and use its best efforts to find an alternative supplier of BUYER Supplies. 

5.12 Expiration Dating. Unless otherwise specified in the Specifications or any Work Order, in no event shall SUPPLIER deliver any
Product to BUYER with remaining expiration dating at the time of delivery of less than 21 months. At BUYER’s sole-discretion, short dated Products may be accepted on a
case-by-case basis. 
 6. Quality Assurance and Documentation.

 6.1 Process. SUPPLIER shall conduct all quality control and process testing in accordance with the Specifications, the cGMP,
and SUPPLIER’s standard operating procedures. SUPPLIER shall conduct sterility and endotoxin testing of Product at its expense. 
 6.2
Documentation. SUPPLIER shall provide BUYER with a copy of the batch documentation for each lot of Product. Upon request, SUPPLIER shall provide BUYER with copies or summaries of other documents or data created or maintained by SUPPLIER in
the ordinary course of manufacturing the Product. SUPPLIER shall, if requested by BUYER, and for an additional charge to be agreed upon, use commercially reasonable efforts to assist BUYER with the preparation of all or any part of a regulatory
submission by BUYER or other special reports, documents, or data not created or maintained by SUPPLIER in its ordinary course of business. 

 7. Quality Assurance, Sampling and Inspections By BUYER. 

7.1 Inspection. On an annual basis, or as needed for cause where quality issues are identified, BUYER’s employees shall have the
right, at a mutually agreeable time and upon mutually agreeable terms, during SUPPLIER’s regular business hours, to enter the Facilities for the purpose of observing the manufacturing of the Product, inspecting the quality of finished Product,
obtaining samples of Product, and/or conducting quality assurance audits. BUYER shall have the right to suspend orders until correction in the event it uncovers material manufacturing or Product quality concerns that SUPPLIER is unable or unwilling
to remedy within a reasonable period of time. BUYER’s employees who inspect SUPPLIER’s Facilities shall comply with SUPPLIER’s regulations, rules, and practices, and BUYER assumes all risk of loss and shall indemnify, defend, and hold
SUPPLIER harmless from all liability resulting from the presence of BUYER employees at the Facilities except when due to gross negligence or willful misconduct on the part of SUPPLIER or its employees. 

7.2 Notification of Inspection. Within two (2) days of being notified of (a) any inspections by the FDA or other Regulatory
Authorities involving or pertaining to the Product, (b) any pending or threatened litigation, governmental investigation, proceeding, or action involving or pertaining to the Product, or (c) any defective, adulterated, or misbranded Product or
any information suggesting that the Product may fail to meet the Specifications or may otherwise be defective, SUPPLIER shall notify BUYER in writing, or BUYER shall notify SUPPLIER in writing, as the case may be, of the preceding. 

7.3 Recall and Adverse Drug Events. If any Regulatory Authority or other government agency or court shall request or require the recall
of all or some of the Product or require the dissemination of information regarding the Product, BUYER shall immediately notify SUPPLIER of such recall or required dissemination and shall consult with SUPPLIER regarding the timely compliance with
all applicable laws and regulations. In addition, BUYER is responsible for compliance with the requirements of the Regulatory Authorities concerning the reporting of adverse effects, which may occur as the result of the use of Product covered by
this Agreement. BUYER will be responsible for Periodic Safety Reporting. SUPPLIER shall be responsible for the costs of any recall or dissemination of information regarding the Product due to its failure to comply with the Specifications, cGMPs or
BUYER instructions. Additionally, at BUYER’s sole discretion, SUPPLIER shall either (i) reimburse BUYER for the Product Price of the recalled units, or (ii) replace the recalled units at no charge. 

7.4 Safety Procedures. BUYER shall supply SUPPLIER with Material Safety Data Sheet and the U.S. Department of Transportation Hazard
Classification for each Product, all API, and for all BUYER Supplies. SUPPLIER and BUYER shall mutually develop safety procedures for the handling and manufacture of the Product and treatment or disposal of wastes relating thereto that comply with
all federal and state environmental 

 
and occupational safety and health requirements. Such procedures shall be included in a separate document and shall be followed by SUPPLIER in performing services under this Agreement. SUPPLIER
shall, in accordance with BUYER instructions, ship rejected API, Product, and BUYER Supplies to such destination as BUYER’s instructions shall designate in writing. The expense for disposal or reclamation of rejected Product, API, BUYER
Supplies, and other waste shall be borne by BUYER; provided, however, the expense for disposal of rejected Product due to failure of SUPPLIER to perform its obligations under this Agreement shall be borne by SUPPLIER. SUPPLIER will not dispose of
rejects or waste without prior written consent from BUYER. 
 7.5 Lot Number and Expiry Date. BUYER will provide directly, or with
instructions, which will enable SUPPLIER to develop, a lot number and expiry period for each lot of Product manufactured by SUPPLIER. 
 7.6
Product Inspection. SUPPLIER will test and inspect each lot of Product for compliance with Specifications, and shall certify in writing such compliance to BUYER, prior to release and shipment to BUYER. If within 30 days after receipt of pre-shipment samples or the lot of Product by BUYER at its facility, BUYER notifies SUPPLIER in writing that such lot contains Non-Conforming Product as determined by any
information available to BUYER, SUPPLIER shall replace Non-Conforming Product at SUPPLIER’s expense (such expense to include the cost of API, BUYER Supplies, and all components and other materials) within
forty-five (45) days of such notice. SUPPLIER shall pay for shipping charges to deliver such replacement Product to BUYER. Non-Conforming Product shall, at BUYER’s election, either (i) be
returned to SUPPLIER within a reasonable period of time, or (ii) be destroyed by BUYER at SUPPLIER’s expense with proof of destruction. Notwithstanding the foregoing, if BUYER first discovers any nonconformance that would not have been
readily discoverable from a review of the associated documentation provided by SUPPLIER or the packaging for a particular Product shipment at the time of delivery (a “Latent Defect”), BUYER shall have a continuing right to notify SUPPLIER
within thirty days after the discovery of the Latent Defect. 
 7.7 Disputes with Respect to Rejection. If SUPPLIER disputes
BUYER’s rejection of all or part of any shipment of the Product, and such dispute is not resolved by mutual agreement between the parties within sixty (60) days of BUYER’s notice of rejection, such dispute shall be resolved by an
independent FDA approved testing organization or consultant of recognized repute within the U.S. pharmaceutical industry mutually agreed upon by the parties, the appointment of which shall not be unreasonably withheld or delayed by either party. The
determination of such testing entity with respect to all or part of any shipment of the Product shall be final and binding upon the parties, but only as to the reasons given by BUYER in rejecting the shipment or portion thereof and shall have no
effect on any matter for which said entity did not render a determination. The fees and expenses of the third party making the determination shall be paid by BUYER if the Product is found to be in compliance with the Specifications, cGMPs, and BUYER
instructions; otherwise, such fees and expenses shall be paid by SUPPLIER. 

 8. Warranty. 

8.1 SUPPLIER Warranty. SUPPLIER warrants that it shall manufacture and supply the Product in compliance with this Agreement, and that
the Product, when delivered to the Carrier, will meet the Specifications and shall not be Non-Conforming Product; provided, however, this warranty shall not apply to defects in Product (i) resulting from
or occurring despite SUPPLIER’s compliance with the Specifications, cGMPs, and any express instruction of BUYER, (ii) resulting from the quality or suitability of any BUYER Supplies, or (iii) if the Product is abused, altered,
improperly stored, or repackaged after leaving SUPPLIER’s possession. No warranty is made as to the quality or suitability of any BUYER Supplies or the Product Performance Characteristics or other performance characteristics of the Product.
Notwithstanding anything contained herein, in no event shall SUPPLIER’s liability with respect to a claim whether by BUYER or any third party arising out of or relating to SUPPLIER’s alleged breach of warranty exceed the limit of insurance
required under section 10.1 of this Agreement. 
 8.2 Warranty Procedures. To claim any rights or to enforce any warranty provisions
against SUPPLIER, written notice of a warranty claim must be given by BUYER to SUPPLIER within one hundred eighty (180) days after the Product is delivered to the Carrier. Any Product that BUYER believes breaches the warranty set forth in this
section must be held by BUYER for SUPPLIER’s inspection and testing and, upon SUPPLIER’s request, returned to original Ex-Works place of shipment point, freight prepaid. Upon SUPPLIER’s
reasonable determination that the Product is defective and that such defect is due to SUPPLIER’s failure to comply with the Specifications, the cGMP, or other negligent or wrongful act or omission by SUPPLIER, SUPPLIER shall, at BUYER’s
election, either (i) manufacture, package, and label additional Product to replace such defective Product at the original Ex-Works place of shipment point (subject to BUYER providing, at SUPPLIER’s
expense, necessary API and BUYER Supplies); or (ii) credit BUYER with an amount equal to the costs of all API and BUYER Supplies in the defective Product. Upon SUPPLIER’s reasonable determination that the Product is not defective, SUPPLIER
and BUYER shall submit the Product to an independent third party for testing. If such third party determines that the Product is defective and that such defect is due to SUPPLIER’s failure to comply with the Specifications, the cGMP, or other
negligent or wrongful act or omission by SUPPLIER, SUPPLIER shall, at BUYER’s election, either (i) manufacture, package, and label additional Product to replace such defective product at the original
Ex-Works place of shipment point (subject to BUYER providing, at SUPPLIER’s expense, all necessary API and BUYER Supplies); or (ii) credit BUYER with an amount equal to the costs of all API and BUYER
Supplies in the defective Product. If such third party determines that the Product is not defective or that such defect is not due to SUPPLIER’s failure to comply with the Specifications, the cGMP, or other negligent or wrongful act or omission
by SUPPLIER, then BUYER shall pay the expenses associated with such third party testing and shall accept and pay for the Product. 
 8.3
Exclusive Remedy. The foregoing is BUYER’s sole and exclusive remedy against SUPPLIER for breach of warranty, breach of contract, tortious acts, or any other legal theory arising out of or related to this Agreement. In no event shall
SUPPLIER be liable for incidental or consequential damages. 

 8.4 Other Warranties. ALL OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT
LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE EXPLICITLY DISCLAIMED. 
 9. Indemnification for
Third Party Claims. 
 9.1 SUPPLIER Indemnification. SUPPLIER shall indemnify and hold BUYER harmless from any damage,
expense, loss, or liability, including reasonable attorney’s fees, arising out of or resulting from any third party claims against BUYER, where SUPPLIER is at fault by reason of (i) defect of the Product which would be a defect covered
under Section 8, (ii) negligence of willful misconduct of SUPPLIER, or (iii) breach of this Agreement, including failure to perform any act required by or in compliance with SUPPLIER’s obligations under this Agreement or another
breach of this Agreement; provided, however, that SUPPLIER shall not have any obligation to indemnify BUYER to the extent a claim results from the gross negligence or willful misconduct of BUYER. BUYER shall give SUPPLIER notice of any claim for
which BUYER may be entitled to indemnification and shall cooperate with SUPPLIER in the defense of such claims. Notwithstanding the foregoing, at its election, and at its own expense, SUPPLIER (or its insurers) may assume direction and control of
the defense of any such claim. 
 9.2 BUYER Indemnification. BUYER shall indemnify and hold SUPPLIER harmless from any damage,
expense, loss, or liability, including reasonable attorney’s fees, arising out of or resulting from any third party claims made or threatened against SUPPLIER by reason of (i) any failure of BUYER to comply with any law or regulation
regarding the possession, distribution, labeling, or sale of the Product, (ii) the gross negligence or willful misconduct of BUYER, or (iii) any Product Performance Characteristics of a Product that is in compliance with the Specifications
and cGMP; provided, however, that BUYER shall not have any obligation to indemnify SUPPLIER to the extent a claim results from the negligence or willful misconduct of SUPPLIER or SUPPLIER’s breach of this Agreement. SUPPLIER shall give BUYER
notice of any claim for which SUPPLIER may be entitled to indemnification and shall cooperate with BUYER in the defense of such claims. 
 10.
Insurance. 
 10.1 SUPPLIER. SUPPLIER shall maintain (i) products liability insurance with a minimum limit of
$10,000,000; (ii) comprehensive general liability insurance with minimum limits of $2,000,000 for each of bodily injury and property damage; and (iii) fire and casualty insurance on its Facilities and their contents, exclusive of BUYER’s
Supplies and exclusive of Product to the extent of the value of BUYER’s Supplies which have become a part of said Product. Such policies of insurance shall provide that BUYER will be notified at least thirty (30) days prior to any
cancellation. BUYER shall be named as an additional insured on all such policies and certificates evidencing such insurance shall be provided to BUYER upon request. 

 10.2 BUYER. BUYER shall maintain (i) products liability insurance with a minimum
limit of $5,000,000; (ii) comprehensive general liability insurance with minimum limits of $2,000,000 for each of bodily injury and property damage; and (iii) fire and casualty insurance, or such other forms of coverage BUYER may desire, on
BUYER Supplies and on Product to the extent of the value of BUYER Supplies which have become a part of such Product, in such amounts as BUYER may desire. Such policies of insurance shall provide that SUPPLIER will be notified at least 30 days prior
to any cancellation. Certificates evidencing such insurance shall be provided to SUPPLIER upon request. 
 11. Confidential Information. 

11.1 Definition. Confidential Information for purposes of this Agreement shall mean any and all trade secrets, know-how of or data about each of the parties, their clients, or their operations, and other matters of a confidential or proprietary nature, including, without limitation, the Product and the Specifications, but
shall not include any of the following information: 
 (i) information which was known to the receiving party, prior to receipt from the
delivering party, as evidenced by the receiving party’s written records; 
 (ii) information which was in the public domain or generally
known to the trade at the time of receipt from the delivering party; 
 (iii) information which, other than by breach of this Agreement,
enters the public domain or becomes generally known to the trade; 
 (iv) information which is disclosed to the receiving party by a third
party who is free to make such disclosure; 
 (v) information which is independently developed by the receiving party without use of the
delivering party’s Confidential Information; or 
 (vi) information which is required to be disclosed by law, regulatory,
administrative, or judicial order. 
 11.2 Term. During the Term and any extension of this Agreement and for a period of five
(5) years thereafter, the parties shall not disclose, communicate, or otherwise make available to any other party and shall not use or deal with in any manner, except as permitted by this Agreement, any Confidential Information of the other;
provided, that with respect to any Confidential Information that constitutes a trade secret of a party, this covenant shall continue for as long as the same remains a trade secret of that party. 

 11.3 Use. Each party agrees to use the Confidential Information of the other only for
the purpose of performing its obligations under this Agreement; shall not copy any Confidential Information of the other except as necessary to perform its obligations under this Agreement; shall limit dissemination of the Confidential Information
of the other to only those of its employees who have a need to know; and shall return all Confidential Information of the other, including any copies, upon the earlier of such party’s request or the termination of this Agreement; provided,
however, a party may retain a copy of the Confidential Information of the other as may be required by law or regulation for record keeping purposes, 

11.4 Disclosure. A party may disclose Confidential Information of the other party to a third person if it is required to do so by
subpoena, court order, law, or regulation. In such event, the party shall, in advance of the disclosure if practical, notify the other of such required disclosure. Each party agrees that the Confidential Information of each party is vital to the
business interests of each party and that any disclosure or unauthorized use thereof would cause irreparable harm. Each party may specifically enforce the obligations of the other under this paragraph, by injunction or otherwise, in addition to and
not in limitation of any other remedies that a party may have at law or in equity. 
 11.5 Discoveries. Discoveries or inventions by
SUPPLIER made in the course of performing this Agreement shall become the property of (a) BUYER, if such discovery or invention relates specifically to the Product or its formulation; or (b) SUPPLIER, if such discovery or invention
improves upon or relates to general manufacturing or production methods applicable to a variety of pharmaceutical products or does not otherwise relate specifically to the Product or its formulation. 

11.6 Prior Agreement. The Parties acknowledge that they are parties to that certain Mutual Confidential Disclosure Agreement by and
between them and having an Effective Date of July 7, 2020 (“the CDA”), and that the CDA remains in full force and effect. The provisions of this Section 11 are intended to supplement, and not to replace, the provisions of the CDA.

 12. Term and Termination. 

12.1 Term. This Agreement shall be effective from its date and shall continue in effect for five (5) years from the date of
shipment to BUYER of the first commercial production of any Product hereunder with successive annual (1 year) renewals, unless earlier terminated as provided herein. Written notification of intent by a Party to terminate this Agreement must be
received by the other Party no less than three (3) months prior to the end of the Agreement and, in the absence of such notice, the annual (1 year) renewal clause will apply. 

12.2 Termination. Either party may terminate this Agreement for a material breach by the other party by giving the breaching party
written notice, specifying the breach relied on, and giving the breaching party thirty (30) days to cure such breach. If the breach has not been cured (or the breaching party has not commenced a good faith effort to cure) at the end of the
thirty (30) day period, then, upon notice thereof to the breaching party by the other, this Agreement shall terminate. 

 12.3 Bankruptcy. If either party shall file or have filed against it a petition in
bankruptcy, make an assignment for the benefit of its creditors, or have a receiver appointed for its assets, which action shall not be vacated within 60 days after such action, then the other party may terminate this Agreement immediately upon
written notice. 
 12.4 Termination by Mutual Consent. BUYER and SUPPLIER may terminate this Agreement upon mutual consent on the
terms and conditions mutually agreed to in a letter of termination executed by BUYER AND SUPPLIER. The terms and conditions contained in such letter of termination (a) may conflict with or add to the terms and conditions of this Agreement; and
(b) shall supersede the terms and conditions of this Agreement, including with respect to survival. 
 12.5 FDA Warning Letter.
This Agreement will terminate only with respect to the affected Product or in its entirety, at the sole discretion of BUYER, immediately upon a ten (10) day written notice by BUYER, following issuance by the US FDA of a “Warning
Letter” to SUPPLIER with respect to one or more of its facilities used, or to be used, to manufacture, test, validate, label, package or store Product. 

12.6 Discontinued Product. BUYER may terminate this Agreement with respect to a specific Product upon 6 (six) months written notice in
the event such Product is discontinued for any reason. 
 12.7 Customer Complaints. BUYER may terminate this Agreement with respect to
a specific Product upon thirty (30) days’ notice in the event that BUYER receives more than 100 documented customer complaints related to Product quality in any one calendar year, which complaints are regarding such Product and due to
reasons that are within SUPPLIER’s control. 
 12.8 Incomplete Tech Transfer. BUYER may terminate this Agreement with respect to
a specific Product upon thirty (30) days’ written notice in the event the Tech Transfer is not complete (including receiving all necessary approvals from FDA) within two (2) years from the Effective Date. 

12.9 Profit Margin. BUYER may terminate this Agreement with respect to a specific Product upon thirty (30) days’ written
notice in the event BUYER’s Gross Profit Margin is below 40% for any two (2) consecutive quarters. In such event, all outstanding purchase orders and the remaining purchase requirement for the calendar year per Section 2.2 will be paid by
BUYER to Nephron within 30 days of termination. 
 12.10 Product Launch. BUYER may terminate this Agreement with respect to a specific
Product upon thirty (30) days’ written notice in the event such Product is not launched within two (2) years from the Effective Date. 

 12.11 Survival. The termination of this Agreement shall not relieve the parties of any
obligation accruing prior to termination, provided that a Purchase Order outstanding as of the effective date of an early termination shall remain in effect only to the extent of work in progress as of the date of notice of termination. Without
limitation as to other rights and obligations that may survive, Sections 8, 9, 10, 11 and 14 shall survive any termination of this Agreement. 
 13.
Independent Contractor. SUPPLIER is an independent contractor for BUYER and the parties are not partners or joint venturers. Except for the Specifications, BUYER Supplies, and BUYER’s right to assure the quality of SUPPLIER’s
services, SUPPLIER shall furnish all expertise, labor, supervision, and facilities necessary for the manufacture and the supply of the Product, maintain all required governmental permits, and comply with all laws regarding the Facilities. 

14. Waiver of Jury Trial. Each party acknowledges and agrees that any controversy which may arise under this Agreement is likely to
involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement. Each party to this
Agreement certifies and acknowledges that (a) no representative of any other party has represented, expressly or otherwise, that such other party would not seek to enforce the foregoing waiver in the event of a legal action,
(b) such party has considered the implications of this waiver, (c) such party makes this waiver voluntarily, and (d) such party has been induced to enter into this Agreement by, among other things, the mutual waivers and
certifications in this section 
 14. 
 15.
Labeling. Product labeling (primary, secondary, insert) and government filings may indicate that the Product has been manufactured for BUYER by SUPPLIER. Except as required by applicable law and regulations, or to seek Regulatory
Authorities’ approval, neither party shall make any other use of the other party’s name, trademarks, or trade dress without the other party’s express prior written approval. 

16. Notices. All notices to be given under this Agreement shall be in writing and shall be delivered personally, by facsimile machine with
a copy mailed by certified mail, or by certified mail postage prepaid, to the following addresses: 
 If to BUYER: NeuroRx, Inc. 

913 N. Market Street, Suite 200 

Wilmington, Delaware 19801 
 USA

 Attention: Jonathan Javitt, MD, MPH; CEO 

Email: jjavitt@neurorxpharma.com 
 If to
SUPPLIER:    Nephron SC, Inc., and Nephron Pharmaceuticals Corporation, subsidiaries 
 of Nephron, Inc. d/b/a NEPHRON
PHARMACEUTICALS 
 CORPORATION 

4500 12th Street Extension 

 West Columbia, SC 29172 

United States of America 

Attention: Lou Kennedy, CEO 

Facsimile: (803) 509-6034 

Notices shall be effective upon receipt if personally delivered; on the first business day following the date of facsimile transmission or email delivery; or
on the third business day following the date of mailing. A party may change the address for notices by notifying the other party of such change in accordance with this Section. 

17. Assignment and Subcontracting. This Agreement shall not be assigned by either party without the prior written consent of the other party.
SUPPLIER may use subcontractors in the performance of this Agreement only with BUYER’s prior written consent. 
 18. Debarment.
SUPPLIER and BUYER represent that they have not been debarred under 21 U.S.C. § 335a or convicted of a felony for conduct relating to the regulation or handling of any drug product and will not use in any capacity in the performance of this
Agreement or any Work Order the Services of any person or entity currently or ever debarred under 21 U.S.C. § 335a or convicted of a felony for conduct relating to the regulation or handling of any drug product 

19. Amendments. This Agreement may only be amended by a written agreement duly executed by the parties. 

20. Force Majeure. The period for which performance (other than the payment of money) is required by a party shall be extended by the
period during which such party is unable to perform due to strikes, acts of God, war, shortages or unavailability of supplies, or other causes beyond the party’s reasonable control. Either party shall have the right to terminate this Agreement
in the event force majeure event continues for longer than 90 days. 
 21. Choice of Law and Venue. This Agreement is governed by and shall be
construed in accordance with the laws of the State of Delaware, notwithstanding any conflict-of-laws rule or principle that might refer the governance or the
construction of this Agreement to the law of another jurisdiction. 
 22. Choice of Forum. Each party irrevocably and unconditionally
agrees that it shall not commence any action, litigation or proceeding of any kind whatsoever against the other party in any way arising from or relating to this Agreement, including all exhibits, schedules, attachments and appendices attached
hereto and thereto, and all contemplated transactions, including contract, equity, tort, fraud and statutory claims, in any forum other than a United States District Court in South Carolina or, if such court does not have subject matter
jurisdiction, the courts of the State of South Carolina sitting in Columbia, and any appellate court from any thereof. Each party irrevocably and unconditionally submits to the exclusive jurisdiction of such courts and agrees to bring any such
action, litigation or proceeding only in a United States District Court for South Carolina or, if such court does not have subject matter jurisdiction, the courts of the State of South Carolina sitting in Columbia. Each party agrees that a final
judgment in any such action, litigation or proceeding is conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable laws. 

 23. Waiver. The waiver by any party of a breach of any provision of this Agreement
shall not operate as a waiver of any subsequent breach. 
 24. Recitals. The Recitals are an integral part of this Agreement. 

25. Headings. The headings of the sections or paragraphs of this Agreement are included for convenience only and shall not affect the meaning of
this Agreement. 
 26. Binding Effect. This Agreement shall be binding upon the successors and assigns of the parties. 

27. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
Agreement. 
 28. Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such
invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. 

 IN WITNESS WHEREOF, the parties have entered into this Agreement as of the
date first above written. 
  

									
	NEURORX, INC.	 	NEPHRON PHARMACEUTICALS CORPORATION
					
	By:	 	 /s/ Jonathan Javitt
	  		 	By:	 	 /s/ Lou Kennedy

	Name:	 	Jonathan Javitt	  		 	Name:	 	Lou Kennedy
	Title:	 	CEO	  		 	Title:	 	CEO
	Date:	 	8/27/2020	  		 	Date:	 	08/25/2020

 EXHIBIT A 

Product 
  

											
	 Product
	  	 Active

Ingredients
	  	 Strength
	  	 Dosage
Form
	  	 Ampoule Sizes
	  	 Reference
Listed Drug

	Vasoactive Intestinal Peptide [VIP] in Sodium Chloride (0.9% saline)	  	 RLF – 100

(Aviptadil)
	  	 1 mg / 10 mL

(100 mcg / mL)
	  	Injection	  	10 mL fill in 10 mL syringe – 5 syringes per carton	  	 Not
 Applicable

	Vasoactive Intestinal Peptide [VIP] in Sodium Chloride (0.9% saline)	  	 RLF – 100

(Aviptadil)
	  	100 mcg / 2 mL (50 mcg / mL)	  	Injection	  	2.0 mL fill in 3.0 mL syringe – 5 syringes per carton	  	 Not
 Applicable

 EXHIBIT B 

Product Specifications 
 To be
determined 

 EXHIBIT C 

Product Pricing and Batch Size 

[***] 

 EXHIBIT D 

BUYER Supplies 
 Buyer will secure and supply all
API for duration of production unless otherwise agreed to by both parties 

 EXHIBIT E 

SUPPLIER Supplies 
 SUPPLIER to supply excipients,
components, packaging, and other materials and supplies for the Product. 

 EXHIBIT F 

Activity/Responsibility Summary 
  

					
	 Activity / Responsibility
	  	BUYER	  	SUPPLIER
	 Supply of API
	  	X	  	
	 Purchase of Raw Materials
	  	X	  	
	 Purchase Packaging Components
	  		  	X
	 API Testing and Release
	  		  	X
	 Packaging Component Testing and Release
	  		  	X
	 Maintenance of Manufacturing Equipment
	  		  	X
	 Maintenance of Packaging Equipment
	  		  	X
	 Maintenance of Analytical Equipment
	  		  	X
	 Calibration of Manufacturing Equipment
	  		  	X
	 Calibration of Packaging Equipment
	  		  	X
	 Calibration of Analytical Equipment
	  		  	X
	 Storage of raw Materials
	  		  	X
	 Storage of Packaging Components
	  		  	X
	 Storage of Finished Product
	  	X	  	
	 Weigh/Dispense API
	  		  	X
	 Weigh/Dispense excipients
	  		  	X
	 Manufacture of finished product, including three exhibit batches
	  		  	X
	 Inspection and secondary packaging
	  		  	X
	 In-process testing
	  		  	X
	 Labeling per applicable laws and requirements
	  		  	X
	 Review and Approve Labeling Proofs
	  	X	  	
	 Finished product release testing
	  		  	X
	 Finished product stability testing
	  		  	X
	 Review and Disposition of Master Batch Record
	  		  	X
	 Review and Disposition of Packaging Record
	  		  	X
	 Final Batch Release
	  		  	X
	 Arrange for Shipping of finished Product
	  	X	  	X
	 Prepare and Approve Certificate of Compliance
	  		  	X
	 Facilities qualification, protocol, execution, completion, report
	  		  	X
	 Cleaning procedures, validation
	  		  	X
	 Analytical Methods for Cleaning Validation
	  		  	X
	 Equipment qualification, protocol, execution, completion, report and approval, safety
qualification
	  		  	X
	 Validation, protocol, execution, completion report and approval
	  		  	X
	 Standard Operating Procedures
	  		  	X
	 SOP Training
	  		  	X

					
	 Maintenance of Training Records
	  		  	X
	 Master Batch Record
	  		  	X
	 Packaging Batch Record
	  		  	X
	 Retention of Batch Records
	  		  	X
	 Storage of Retain Samples
	  		  	X
	 Maintenance/Administration of Retain Samples
	  		  	X
	 Conduct Annual Product Review
	  	X	  	X
	 Health and Safety Programs in accord with State, Local and Federal Regulations
	  		  	X
	 Training on relevant health and safety issues
	  		  	X
	 Documented Health and Safety Procedures
	  		  	X
	 Prepare documents for FDA Submission
	  	X	  	X
	 Submit amendments/supplements to current NDA /

ANDA / 505(b)(2) filing
	  	X	  	
	 Maintaining facility registrations, including paying GDUFA Finished Dosage Form Establishment
Fee:
	  		  	X
	 Provide technical dossier for each of the Products to SUPPLIER
	  	X	  	
	 Perform testing required for Technical Transfer
	  		  	X
	 Drug Listing of each Product
	  	X

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]